Remarkably, mice that were treated with PD901/Abemaciclib exhibited a dramatic reduction in mammary tumour growth relative to vehicle-treated mice (Fig. 5f, g), which was accompanied with reduced proliferation (Ki67) (Fig. 5h). Here, MKI67 is linked to breast cancer.